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Background: This study was conducted to identify factors associated with early mortality (30-day, 60-day) among patients with cirrhosis and portal
hypertension who undergo transjugular intrahepatic portosystemic shunts (TIPS).
Methods: Consecutive patients who underwent TIPS between January 1993 and December 2008 were included in the study. Clinical, laboratory, and
procedural data were collected for all patients by retrospective chart review. Qualitative variables were compared by chi square test and quantitative
variables by Student’s t-test. Multinomial logistic regression was used for multivariate analysis.
Results: A total of 643 patients had complete data and were included in the study. The incidence of 30-day mortality in the study group was 17.4% (112/
643), and the incidence of 60-day mortality was 22.6% (145/643). Univariate analysis was carried out comparing these risk factors in patients stratiﬁed by
30-day and 60-day mortality. On univariate analysis, pre-TIPS bilirubin >2.0 mg, pre-TIPS albumin <2.5 gm/dL, pre-TIPS international normalized ratio
>2, pre-TIPS creatinine >2.0, pre-TIPS MELD (Model for End-stage Liver Disease) score >20, pre-TIPS hepatic venous pressure gradient (HVPG)
>20 mmHg, higher pre-TIPS alanine transaminase, and higher pre-TIPS aspartate transaminase were found to be predictors of both 30- and 60-day
mortality. Multivariate analysis showed pre-TIPS creatinine >2 mg/dL, pre-TIPS MELD levels >20 and HVPG (hepatic venous portal gradient)
>20 mmHg to be independent and signiﬁcant predictors of both 30- and 60-day mortality. For every 1 mg/dL rise of creatinine exceeding 2 mg/dL, the
odds of 30-day mortality increased by 80% [odds ratio ¼ 1.8 (1.3–2.4)]. A pre-TIPS HVPG of more than 20 mmHg was found to be correlated with worsened
30-day and 60-day mortality in patients with variceal bleed but not in patients with ascites or hydrothorax.
Conclusion: Stepwise model selection determined that serum creatinine >2.0 mg/dL, MELD >20, and pre-TIPS HVPG >20 mmHg were independent
predictors of early mortality. A pre-TIPS HVPG of more than 20 mmHg was found to be correlated with worsened 30-day and 60-day mortality in patients
with variceal bleed but not in patients with ascites or hydrothorax.
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Cirrhosis and its complications are major causes of morbidity
and mortality in the US. The National Center for Health Statistics
reports chronic liver disease and cirrhosis to be the 12th leading
cause of death in the US, causing around 27,000 deaths per year.1
When common complications of cirrhosis, like variceal hemor-
rhage and ascites, fail to respond to standard medical treatment,
transjugular intrahepatic portosystemic shunt (TIPS) is being
increasingly used in their management.2,3 The technical reﬁne-
ments introduced since TIPS was ﬁrst pioneered, in 1969,4 have
improved its efﬁcacy and clinical outcomes.5,6
TIPS is a percutaneously created shunt within the liver between
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emergency basis. Morbidity and mortality associated with TIPS
placement are much lesser than those associated with alternatives
like surgical portosystemic shunting7,8; however, TIPS itself may be
followed by complications like shunt dysfunction, bleeding, wors-
ening of hepatic encephalopathy, and liver failure.7,9 The early
mortality after TIPS has been reported to be high in various studies,
ranging from 25% to 35%.10–13 It is thus important to identify and
optimize preventive measures or exclude patients who are at high
risk for complications and mortality after this procedure.
In patients with complications of portal hypertension, TIPS has
been proven as one of the most effective palliative therapies. The
purpose of identifying these risk factors is not to deny patients
a potentially life-saving procedure, but to enable us to discussal, Atlanta, GA, USA
icine, Atlanta, GA, USA
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Table 1 Demographic and Clinical Characteristics of Patients
Factor Categories All patients
(n ¼ 643)
Age < 59 y 581 (90.4%)
> 60 y 62 (9.6%)
Sex Male 399 (62.1%)
Female 244 (37.9%)
Race Caucasian 565 (87.9%)
African American 53 (8.2%)
Other 25 (3.9%)
MELD score < 15 426 (80.2%)
 15 105 (19.8%)
Pre-TIPS creatinine  2.0 mg/dL 555 (86.3%)
> 2.0 mg/dL 88 (13.7%)
Pre-TIPS bilirubin < 2 mg/dL 353 (54.9%)
 2.0 mg/dL 290 (45.1%)
Pre-TIPS INR < 2.0 557 (86.6%)
 2.0 86 (13.4%)
Pre-TIPS albumin < 2.5 gm/dL 257 (40.0%)
 2.5 gm/dL 386 (60.0%)
HCV Positive 189 (29.4%)
Negative 436 (67.8%)
Indication for TIPS Elective 576 (89.6%)
Emergent 67 (10.4%)
Clinical indication Variceal bleed 250 (38.9%)
Refractory ascites 309 (48.1%)
Refractory hydrothorax 68 (10.6%)
Portal vein thrombosis 8 (1.2%)
Others 8 (1.2%)
Type of TIPS stent Covered 207 (32.2%)
Uncovered 436 (67.8%)
Size of stent < 10 mm 127 (19.8%)
> 12 mm 516 (80.2%)
Pre-TIPS ALT (IU/L) Mean (range) 51 (6–911)
Pre-TIPS AST (IU/L) Mean (range) 77 (5–2344)
Pre-TIPS platelet
count (cells/mm3)
Mean (range) 116 (15–779)
Pre-TIPS HVPG mmHg 17.4 (2–70)
Post-TIPS HVPG mmHg 5.5 (0–21)
ALT, alanine transaminase; AST, aspartate transaminase; HCV, hepatitis C virus;
HVPG, hepatic venous pressure gradient; INR, international normalized ratio; MELD,
Model for End-stage Liver Disease; TIPS, transjugular intrahepatic portosystemic
shunt.
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physicians, and ultimately, to make reasonable decisions in the best
interest of patients. Several authors have described high risk factors
associated with early mortality after TIPS.14–16 In spite of a few
proposed prognostic indices, a consensus on the high risk factors
which mandate exclusion from therapy has not been reached. In
this study, we have explored predictors of 30-day and 60-day
mortality among a large cohort of patients who underwent TIPS
at a single institution over a 15-year period.
Methods
Study population
This retrospective study was approved by the institutional
review board. All patients with end-stage liver disease who under-
wentTIPSbetween1993and2008were included inour studygroup.
Right heart failure, pulmonary hypertension, severe infection,
severe hepatic encephalopathy, and multiple hepatic cysts were
considered to be absolute contraindications and portal vein
thrombosiswas considered tobe a relative contraindication for TIPS.
Patients were stratiﬁed into two groups based on their mortality
status at 30 or 60 days after performance of TIPS procedure.
Data collection
Retrospective chart review was used to collect demographic,
clinical, laboratory, radiologic, and procedure-related data. Clinical
features recorded include age, gender, race, etiology of cirrhosis, and
indication for TIPS. Pre-TIPS laboratory values noted include serum
bilirubin, creatinine, albumin, platelet count, aspartate transaminase
(AST), alanine transaminase (ALT), and international normalized ratio
(INR). MELD (Model for End-stage Liver Disease) scores were calcu-
lated from the laboratory values. Procedure-related data collected
include date of TIPS, pre- and post-TIPS hepatic venous pressure
gradient (HVPG), number of revisions, patency rates, types of stent,
and size of TIPS stent.
TIPS procedure
The TIPS procedure has been described numerous times else-
where.17 Themajority of our TIPS procedures were performed under
general anesthesia according to operator and/or patient preference
using either the Ring or Haskal Transjugular Intrahepatic Access Sets
(CookMedical Inc., Bloomington, IN). Right atrial, wedge hepatic, and
portal vein pressures were recorded before balloon dilatation and
stenting. Portal vein, hepatic vein, right atrial pressures, and a portal
venogramwere recorded following shunt placement. To attain a goal
of a post-TIPS portosystemic gradient of 10 mmHg or less, the TIPS
tract and stent were usually dilated to a 10-or 12-mm diameter.
Uncovered stents, primarily theWallstent (Boston Scientiﬁc, Natick,
MA),wereuseduntil theViatorrePTFE-coatedstent-graft (W.L.Gore
andAssociates, Flagstaff, AZ) became available in2000; this stentwas
used almost exclusively since that time. Shunt gradientwas recorded
after the procedure.
Statistics
Patients were stratiﬁed into those who suffered mortality within
30 and 60 days, and those who survived beyond these periods.
Pearson chi square test and Fisher exact probability were used to
compare the distribution of categorical variables. Independent t-tests
were used to comparemeans of continuous variables. Statistical tests
of association were two-sided. Multinomial logistic regression tech-
nique was applied in a stepwise manner to identify risk factorsindependentlyassociatedwithearlydeath.Allpatientswere followed
upuntil death, until theywere lost to followup, or until studyclosure.
The software SPSS 16.0 (SPSS Inc., Chicago, IL) was used for all
statistical analyses.
Results
A total of 643 consecutive patients underwent the TIPS procedure
between 1993 and 2008 and were included in the study. The mean
age of the study group was 54.56 years (range 17–87); 62.1% (399/
643) were male and 87.9% (565/643) were Caucasian. Table 1
describes the demographic, clinical, and procedure-related data of
the studygroup. The incidence of 30-daymortality in the studygroup
was 17.4% (112/643), and the incidence of 60-daymortalitywas 22.6%
(145/643). TIPSwasperformedonanemergentbasis formanagement
of acutely bleeding esophageal varices refractory to medical treat-
ment in 10.4% (67/643) of patients, and on an elective basis in the
remaining 89.6% (576/643) of patients. The most common cause of
death in patients who suffered 30-day mortality was liver failure,
which was seen in 26.8% (30/112) of patients. The other causes of
death were massive gastrointestinal bleed in 17.9% (20/112), renal
failure in 15.2% (17/112), sepsis with multiorgan failure in 11.6% (13/
112), TIPS procedure-related bleeding 3.6% (4/112), and other causes
in 12.5% (14/112). The cause of death could not be discerned in 12.5%
(14/112) of patients.
Univariate analysis was carried out comparing these risk factors
in patients stratiﬁed by 30-day and 60-day mortality (Table 2). On
Table 2 Univariate Analysis of Factors Predicting 30-day and 60-day Mortality
Factor Categories Survived beyond
30 d (n ¼ 531)
30-d mortality
(n ¼ 112)
P Survived beyond
60 d (n ¼ 498)
60-d mortality
(n ¼ 145)
P
Age < 59 y 477 104 0.212 450 131 0.552
> 60 y 54 8 48 14
Sex Male 333 66 0.259 317 82 0.074
Female 198 46 181 63
Race Caucasian 465 100 0.753 434 131 0.310
African American 46 7 46 7
Other 20 5 18 7
MELD score < 20 426 61 < 0.001 405 82 < 0.001
 20 105 51 93 63
Pre-TIPS creatinine  2.0 mg/dL 471 84 < 0.001 447 108 < 0.001
> 2.0 mg/dL 60 28 51 37
Pre-TIPS bilirubin < 2.0 mg/dL 310 43 < 0.001 291 62 0.001
 2.0 mg/dL 221 69 207 83
Pre-TIPS INR < 2.0 469 88 0.006 442 115 0.003
 2.0 62 24 56 30
Pre-TIPS albumin < 2.5 gm/dL 307 79 0.008 211 46 0.013
 2.5 gm/dL 224 33 287 99
HCV Positive 153 36 0.191 144 45 0.301
Negative 367 69 342 94
Clinical indication Variceal bleed 250 59 0.243 241 68 0.549
Refractory ascites 214 36 194 56
Hydrothorax 55 13 53 15
Type of TIPS stent Covered 171 36 0.957 148 39 0.790
Uncovered 360 76 350 106
Size of stent < 10 mm 107 20 0.959 99 117 0.603
> 12 mm 424 92 399 28
Pre-TIPS HVPG < 20 mmHg 347 59 0.010 328 78 0.009
> 20 mmHg 106 33 97 42
Pre-TIPS ALT (IU/L) Mean (range) 84 (8–911) 45 (6–494) < 0.001 43.7 (6–494) 77.8 (8–911) < 0.001
Pre-TIPS AST (IU/L) Mean (range) 139 (12–2344) 64 (5–601) < 0.001 62.9 (5–601) 124.4 (12–2344) < 0.001
Pre-TIPS platelet
count (cells/mm3)
Mean (range) 107 (11–613) 118 (15–779) 0.746 119.7 (10–779) 105.9 (11–613) 0.852
ALT, alanine transaminase; AST, aspartate transaminase; HCV hepatitis C virus; HVPG, hepatic venous pressure gradient; INR, international normalized ratio; MELD Model for
End-stage Liver Disease; TIPS, transjugular intrahepatic portosystemic shunt. P values are statistically signiﬁcant.
Renumathy Dhanasekaran et al. / Early mortality predictors in cirrhosis 65univariate analysis, pre-TIPS bilirubin >2.0 mg, pre-TIPS albumin
<2.5 gm/dL, pre-TIPS INR >2, pre-TIPS creatinine >2.0, pre-TIPS
MELD score >20, pre-TIPS HVPG >20 mmHg, higher pre-TIPS ALT,
and higher pre-TIPS AST were found to be predictors of both 30-day
and 60-day mortality. Age, gender, ethnicity, HCV positivity, indi-
cation for TIPS, type of stent (covered vs. uncovered), and size of
stent were not found to predict early mortality. Multivariate anal-
ysis was carried out using logistic regression model. A signiﬁcance
level of 0.10 in the univariate analysis was used as a cutoff to
include a variable in multivariate analysis. The results of multi-
variate analysis are given in Table 3. Multivariate analysis showed
higher pre-TIPS creatinine levels, higher pre-TIPS MELD score, and
higher pre-TIPS HVPG to be independent and signiﬁcant predictors
of 30-day and 60-day mortality.
We evaluated the relationship between creatinine and 30-day
mortality and found that for every 1 mg rise in creatinine (aboveTable 3 Multivariate Analysis of Factors Predicting 30-day and 60-day Mortality
Factor 30-d mortality 60-d mortality
P OR (95% CI) P OR (95% CI)
Pre-TIPS creatinine 0.020 2.2 (1.4–4.4) 0.004 2.5 (1.3–4.7)
Pre-TIPS MELD 0.050 2.0 (0.9–4.0) 0.027 1.8 (1.1–2.7)
Pre-TIPS HVPG 0.040 1.7 (1.0–2.8) 0.025 2.1 (1.1–3.9)
Pre-TIPS bilirubin 0.176 1.4 (0.8–2.5) 0.321 1.2 (0.8–2.0)
Pre-TIPS INR 0.470 0.8 (0.3–1.6) 0.662 0.7 (0.3–1.3)
Pre-TIPS albumin 0.110 1.5 (0.9–2.5) 0.349 1.2 (0.8–2.0)
Pre-TIPS AST 0.208 0.9 (0.9–1.0) 0.267 0.9 (0.9–1.0)
Pre-TIPS ALT 0.959 0.9 (0.9–1.0) 0.642 0.9 (0.9–1.0)
AST, aspartate transaminase; ALT, alanine transaminase; HVPG, hepatic venous
pressure gradient; INR, international normalized ratio; MELD, Model for End-stage
Liver Disease; TIPS, transjugular intrahepatic portosystemic shunt. P values are
statistically signiﬁcant.2 mg/dL) the risks of 30-day mortality increased by 80% [odds ratio
(OR) 1.8; 1.3–2.4]. The 30-day and 60-day mortality rate in patients
who underwent emergent TIPS was high, at 41.8% (28/67) and
58.2% (39/67), respectively. But the mean pre-TIPS MELD score in
patients who underwent TIPS on an emergent basis was higher
(19.2) than that of patients who underwent elective TIPS (16.7)
(P ¼ 0.012). We divided the patient population into those who
underwent TIPS before and after 2000. The 30-day mortality in
patients underwent TIPS before 2000 was 18.7% (68/364), and in
those who underwent TIPS after 2001 it was 15.8% (44/279)
(P¼ 0.347). The 60-daymortality in patients underwent TIPS before
2000 was 25.0% (91/364), and in those who underwent TIPS after
2001 it was 19.4% (54/279) (P ¼ 0.105). We performed a sub-
stratiﬁcation analyses to evaluate the effect of pre-TIPS HVPG on
early mortality based on the clinical indication for TIPS placement
(Table 4). A pre-TIPS HVPG of more than 20 mmHg was found to be
correlated with worsened 30-day and 60-day mortality in patients
with variceal bleed. However, such a correlation was not found in
patients with refractory ascites or refractory hydrothorax.Discussion
In this study, the incidence of 30-day and 60-day mortality was
found to be 17.4% and 22.6%, respectively. Pre-TIPS creatinine
>2 mg/dL, pre-TIPS MELD >20, and pre-TIPS HVPG >20 mmHg
were found to be independent predictors of both 30-day mortality
and 60-day mortality (Fig. 1). Though the early mortality rates
improved in the current decade compared to the previous, the rates
were not statistically different. A pre-TIPS gradient of more than
20 mmHg was found to be correlated with worsened 30-day and
Table 4 Relationship between Pre-TIPS HVPG and Early Mortality
Indication for TIPS Pre-TIPS HVPG (mmHg) 30-d mortality P 60-d mortality P
Variceal bleed < 20 15.1% 0.03 17.7% 0.04
> 20 26.9% 30.1%
Refractory ascites < 20 12.8% 0.51 20.7% 0.36
> 20 16.9% 27.1%
Refractory hydrothorax < 20 17.4% 0.27 19.5% 0.30
> 20 33.3% 33.3%
HVPG, hepatic venous pressure gradient. P values are statistically signiﬁcant.
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with ascites or hydrothorax.
The early mortality rate reported in our study is similar to the
rates described in a fewother studies analyzing the same data. Table
5 lists a few studies which analyzed factors predicting early
mortality after TIPS.12–16,18 In our study, the common causes of death
were liver failure, recurrent variceal bleeding, renal failure, and
sepsis. The incidence of procedure related mortality was low. This
suggests that the high rate of earlymortality in the post-TIPS period
is related more to the severity of the underlying liver disease and
the indication for TIPS placement rather than the procedure itself.
The shunting of blood from the portal to the systemic circulation via
the TIPS might compromise the hepatic parenchymal blood ﬂow,
thus contributing to the worsening liver function and death.19–21
In our study, renal function was found to be an independent
predictor of early mortality after TIPS (Fig. 2). Every 1 mg raise in
creatinine above 2mg/dLwas associatedwith an increase in the risk
of 30-day mortality by 80% (Fig. 3). Similar results have been pub-
lished before. Patch et al22 also found serum creatinine to be one of
the six independent factors associated with early mortality after
TIPS placement in variceal bleeders. Russo et al even reported
elevated serum creatinine level to be the strongest predictor of
30-day mortality after TIPS placement.23 Acute renal failure has
actually been shown to be associated with higher mortality in allFig. 1. Bar graph showing 30-day and 60-day mortality (y-axis) among patients with
high risk factors (x-axis).
Table 5 Comparison of Studies Analyzing 30-day Mortality
Study Year n Indication for TIPS
Chalasani et al15 2000 129 All indications
Rajan et al12 2002 220 Variceal hemorrhage
Russo et al13 2002 90 All indications
Yoon et al16 2005 73 Acute variceal
bleeding in viral hepatitis
Pan et al18 2008 352 All indications
Tzeng et al14 2009 107 Emergent TIPS
Current study 643 All indications
MELD, Model for End-stage Liver Disease; TIPS, transjugular intrahepatic portosystemicpatients with end-stage liver disease.24,25 However, there are some
case studieswhereperformanceof TIPSwas actuallyassociatedwith
a delayed improvement in creatinine clearance, especially in
patients with ascites.26,27 TIPS has even been used as a therapeutic
modality in small uncontrolled studies for selected patients with
hepatorenal syndrome type 1.28,29 At this point, TIPS appears to
improve renal function in a certain subset of patients but is overall
associatedwith higher earlymortality in patients with renal failure.
Recently, an interdisciplinary working party proposed a revised
classiﬁcation system of renal dysfunction in patients with
cirrhosis.30 If such systems are used to better classify renal
dysfunction in cirrhotics, then we hopefully can identify the subset
of patients inwhomTIPSmight be helpful and the subset inwhich it
would be contraindicated.
MELD score > 20 was found to be an independent predictor of
both 30-day and 60-day mortality. Several earlier studies have
established that MELD score is a useful predictor of both short-term
and long-term survival in patients with end-stage liver
disease.23,31,32 It is interesting to note that Malinchoc et al23 origi-
nally developed the MELD score in 2000 as a predictor of 3-month
mortality after TIPS, and it has been subsequently used to predict
severity of liver disease and for transplant listing.
HVPG is an objective measure of the severity of portal hyper-
tension and usually correlates well with the occurrence of compli-
cations like variceal bleeding. Studies have shown that a fall below
12 mmHg or a reduction in HVPG by at least 20% can prevent
recurrence of variceal bleed and improve survival.33 In almost all the
patients who underwent TIPS at our center, the post-TIPS HVPG was
reduced to less than 12 mmHg and the mean decrease in HVPG
from baseline was 67%. We found that pre-TIPS HVPG greater than
20 mmHg was associated with worse short- and intermediate-term
mortality in patients with variceal bleed. In an earlier study by
Moitinho et al,33 an initial HVPG of  20 mmHg was associated with
a signiﬁcantly longer intensive care unit stay, longer hospital stay,
greater transfusion requirements, and a worse actuarial probability
of survival. This was further validated in a later study which showed
that HVPG remained an independent variable in amodel adjusted by
MELD, ascites, encephalopathy, and age.34 Endpoints Single Topic
Conference on “Portal Hypertension and Variceal Blee-
dingdUnresolved Issues” took place in Atlanta, GA, in 2007 and was
jointly sponsored by the American Association for the Study of Liver30-d mortality Predictive factors
–% Emergent TIPS, Bilirubin > 3 mg/dL
26.0% Bilirubin > 3 mg/dL, Intubated patients,
Child Pugh class C
20.0% Uncontrolled variceal bleeding, coagulopathy,
hyperbilirubinemia, and renal insufﬁciency
31.5% Hyperbilirubinemia (> 3 mg/dL);
serum creatinine level (> 1.7 mg/dL).
11.9% Bilirubin level > 2.5 mg/dL and
creatinine level > 1.2 mg/dL
28.0% Child–Pugh score > 11; MELD2 score > 20
17.4% Emergent TIPS, creatinine > 2 mg/dL and MELD> 20
shunt.
Fig. 2. Kaplan–Meier survival curves comparing survival between patients with serum
creatinine, 2.0 and >2 mg/dL.
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They reported that in patients with decompensated cirrhosis, an
HVPG of 20 mmHg appeared to be the best cutoff for predicting
clinical outcome.35 Earlier studies which have validated this quan-
titative cutoff have involved very small patient populations. Several
other larger studies did not even consider this factor in their analyses.
In our large series, we were able to conﬁrm the signiﬁcance of this
cutoff, which further strengthens its clinical relevance.
This study represents one of the largest numbers of patients
being analyzed although its retrospective nature can be considered
its main limitation. We were unable to use some other prognostic
models like APACHE II (Acute Physiology And Chronic Health
Evaluation) and Child–Pugh score in the analysis due to the
subjective nature of some of the parameters and/or lack of
complete laboratory data. Considering that the study spans
a duration of 15 years, variation exists in selection criteria used and
technique of TIPS performance over the period we have studied.
Traditionally, liver function has been considered to be the main
determinant of outcome after TIPS. Our study does highlight the
role of renal function and the degree of portal hypertension as
factors which also play a signiﬁcant role in determining clinical
outcome. A multicenter prospective trial with uniform patientFig. 3. Bar graph showing incremental 30-day mortality (y-axis) with a unit rise in
serum creatinine (x-axis).selection criteria will be able to identify these risk factors more
accurately.
Conclusion
The 30-day and 60-day mortality after TIPS in this study were
17.4% and 22.6%, respectively. Stepwisemodel selection determined
that serum creatinine > 2.0 mg/dL, MELD > 20, and pre-TIPS HVPG
> 20 mmHg were independent predictors of early mortality. A pre-
TIPS HVPG of more than 20 mmHg was found to be correlated with
worsened 30-day and 60-day mortality in patients with variceal
bleed but not in patients with ascites or hydrothorax.
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